Fortress Biotech Inc (NASDAQ:FBIO) shares are trading lower by 18.5% to $1.49 Friday afternoon after the company announced the pricing of a $8 million registered direct offering and concurrent private placements.
What Happened: Fortress Biotech announced on Thursday that it entered into securities purchase agreements with healthcare-focused institutional investors to sell 3,939,394 shares of common stock at $1.65 per share in a direct offering.
Additionally, the company issued warrants to purchase up to 3,939,394 shares at $1.84 per share, exercisable in six months, expiring in five and a half years. In a separate private placement, the company's Chairman, CEO and President purchased 763,359 shares and warrants at $1.84 per share.
The offerings will raise approximately $8 million in gross proceeds, aimed at general corporate use. A.G.P./Alliance Global Partners is acting as the sole placement agent, and the offerings are expected to close around September 23, 2024.
Read Also: How Apple Stock Could Gain From Friday's S&P 500 Rebalancing: What Investors Should Know
Should I Sell My FBIO Stock?
When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
Shares of Fortress Biotech have decreased by 67.86% in the past year. An investor who bought shares of Fortress Biotech at the beginning of the year would take a loss of $1.22 per share if they sold it today. The stock has fallen 29.9% over the past month, meaning an investor who bought shares on Aug. 1 would see a capital loss of $0.44.
Fortress Biotech shares have an all-time high of $54.75, representing 3637.2% upside from current levels.
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Fortress Biotech stock currently has an RSI of 48.73, indicating neutral conditions.
For access to advanced charting and analysis tools and stock data, check out Benzinga PRO. Try it for free.
FBIO has a 52-week high of $5.28 and a 52-week low of $1.25.